Search This Blog

Monday, April 27, 2026

Intellia Phase 3 for hereditary angioedema meets primary, key secondary endpoints, rolling BLA underway

 

Intellia's Phase 3 HAELO trial of lonvo-z for hereditary angioedema meets primary, key secondary endpoints and rolling BLA to FDA underway

  • Company reports favorable safety profile and targets potential U.S. launch in the first half of 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)